On June 5, 2024, the U.S. FDA’s Vaccines and Related Biological Products Advisory Committee announced that it had unanimously voted to recommend a monovalent JN.1-lineage vaccine composition.

Following the vote, the committee discussed considerations for the selection of a specific JN.1 lineage SARS-CoV-2 strain (e.g., JN.1 or KP.2) and expressed a strong preference for JN.1.